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Background: Heart failure(HF)with preserved ejection fraction (HF-PEF) comprises nearly half of HF patients (pts) who have substantial morbidity 
and mortality(M). Hospitalized HF pts, particularly those with decompensated HF(ADHF),are at high risk after a hospitalization(hosp), but no data 
has been reported for HF-PEF pts from any randomized trial. To understand the hosp burden of HF-PEF pts and M risk post hosp, we examined data 
from the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial (I-PRESERVE). 
Methods: The I- PRESERVE trial randomized 4128 HF pts with LVEF >45% to irbesartan or placebo for a mean follow-up of 49.5 months. First hosp. 
were categorized for primary cause as cardiovascular non-HF (CV), heart failure (HF), and non-cardiovascular (non-CV). All-cause M was ascertained 
post first hosp and post trial entry in those without a hosp. Median times to initial hospitalization were calculated.
Results: Table />Summary: In I-PRESERVE, first hosps were more commonly non-CV with a minority having HF. Early risk for M was substantial 
at 30 days and continued over the post-hosp follow-up period. For the overall study, patients with any hosp had markedly higher M those never 
hospitalized (p<0.0001) and those with a HF cause had the highest M (p<0.0001). 
Conclusion: Any hospitalization in HF-PEF patients is associated with significant subsequent mortality, particularly in those with heart failure as a 
primary cause. Patients without a hospitalization have a low mortality. 
Post Hospitalization Mortality
Hosp. type (n) Median (days) to Hosp 30 day 1 year Overall
CV non-HF (826) 425(161-851) 52 (6.2%) 105(12.7%) 218 (26.3%)
HF (400) 324(139-700 19 (4.8%) 79 (19.7%) 183 (45.8%)
non-CV (1052) 475(167-924) 58 (5.5%) 173 (16.4%) 330 (31.3%)
any hosp (2278) 426(155-851) 129 (5.6%) 357 (15.7%) 731(32.0%)
no hosp (1850) 152 (8.2%)
